Pharma companies are expanding AI partnerships to accelerate biomarker discovery and clinical development. Tempus AI and Merck signed a multi‑year deal to mine de‑identified clinical and molecular data for precision oncology biomarkers, while Evinova — an AstraZeneca‑created AI unit — struck agreements enabling Astellas, Bristol Myers Squibb and AstraZeneca to deploy AI systems for trial design and document management. Merck will use Tempus’ multimodal datasets and Lens platform to prioritize biomarkers and tackle resistance mechanisms. Evinova’s arrangements hinge on shared operational data to set benchmarks and recommend efficiencies across clinical operations. These deals illustrate the industry’s push to operationalize AI across discovery and development, pairing large biopharma portfolios with AI platforms to shorten timelines, de‑risk trials and extract translational signals at scale.